

Clostridium difficile is present in 13 of every 1000 hospital inpatients.¹ Rapid, accurate, and sensitive methods of screening for C. difficile are necessary to maintain good infection control measures and improve patient outcomes.

Advancements in C. difficile Testing

- Guidelines now recommend GDH screening in combination with toxin testing to improve sensitivity.² The C. DIFF QUIK CHEK COMPLETE® test is the only device that simultaneously detects both GDH antigen and Toxins A & B.
- Algorithm testing provides a more complete diagnostic picture than molecular testing alone. The C. DIFF QUIK CHEK COMPLETE® test detects actual antigen and toxins present. Molecular assays indicate if a gene is present, but not if toxins are being produced or causing disease.

Increased Sensitivity with Algorithm Testing


- Sensitivity and Negative Predictive Value (NPV) of GDH are equivalent to PCR when compared to cytotoxicity or toxigenic culture.³⁻⁵
- 99.8% NPV gives you confidence that negative results are accurate.⁶ Repeat testing is no longer recommended for Positive Ag/Positive Tox & Negative Ag/Negative Tox results.
- Approximately 90% of samples can be reported in < 30 min. using the C. DIFF QUIK CHEK COMPLETE® test, improving workflow and effective management of C. difficile infections.⁶



To learn more about cost-effective, sensitive, rapid detection of *C. difficile*, contact your local Alere Representative

Easy to Use*

- Total assay time < 30 min
- Graduated pipet volumes for accurate sampling
- Built-in quality controls in every cassette




*For complete instructions for use, see the package insert.





Testing Algorithm



Clinical Performance Summary

Performance of GDH antigen portion vs. cytotoxicity testing6

n =	1126
Sensitivity	98.7%
Negative Predictive Value (NPV)	99.8%

All data calculated from package insert.

Performance of toxins A & B portion vs. cytotoxicity testing6

n =	1126
Sensitivity	87.8%
Specificity	99.4%
Positive Predictive Value (PPV)	95.8%
Negative Predictive Value (NPV)	98.1%
Correlation	97.8%

Order Information

C. DIFF QUIK CHEK COMPLETE®

Moderately Complex 25 Test Kit / 50 Test Kit

Catalog No. 23900552 (25 Tests) Catalog No. 23900551 (50 Tests) CPT® Codes: 87324 / 87449

Actual reimbursement may vary. Alere cannot guarantee or promise coverage or payment for any particular item or service from any payer or health benefit plan. It is the individual provider's responsibility to Actual reliabilistic facilities appropriate coding for a particular service.

1. Association for Professionals in Infection Control and Epidemiology (APIC). 2008. National Prevalence Study of Clostridium difficile in U.S. Healthcare Facilities.

- 2. American Society for Microbiology (ASM). 2010. A Practical Guidance Document for the Laboratory Detection of Toxigenic Clostridium difficile http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf
- Swindells et al. 2010. J Clinical Microbiology. 48(2): 606-608.
 Quinn et al. 2010. J Clinical Microbiology. 48(2): 603-605.
- 5. Sharp et al. 2010. J Clinical Microbiology. 48(6): 2082-86
- 6. C. DIFF QUIK CHEK COMPLETE® Package Insert, 11/2009
- 7. Fekety, R. 1997. ACG Guidelines for the Diagnosis and Management of Clostridium difficile-Associated Diarrhea and Colitis. Am J Gastroenterology. 92(5): 739-750.

© 2014 Alere. All rights reserved. The Alere Logo and Alere are trademarks of the Alere group of companies. C. DIFF QUIK CHEK COMPLETE, LEUKO EZ VUE and TECHLAB are trademarks of TECHLAB, Inc., under license. The Fisher Healthcare Logo is a trademark of Fisher Scientific Company, L.L.C. 3000232-01 06/14 BN0630146

In the United States:

For customer service, call 1-800-640-0640 To fax an order, use 1-800-290-0290 To order online: www.fisherhealthcare.com

